Fundraising Fox
Hepanova
Gaithersburg, US · California corporation
Find your way into Hepanova
Sign up to see every warm intro you have to Hepanova
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Hepanova team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Hepanova is a clinical-stage biotech developing first-in-class oral small-molecule therapeutics for chronic liver diseases and inflammatory conditions, including MASH, liver fibrosis, and IBD. Its lead candidate, HPN-01, is an oral dual IKKα/IKKβ inhibitor that has completed a U.S. Phase 1 trial.
Founders & leadership
QL
QISHENG LICo-founder
TJ
T. Jake LiangCo-Founder
MN
Mazen NoureddinChief Medical Officer
BX
Belle X. WangChief Operating Officer
EL
Ella LiChief Business OfficerElla Li holds a Ph.D. and is a founding partner of H7 BioCapital, a venture capital firm focused on life science investment and business development in pharmaceuticals. She has over a decade of biotech research experience with publications in leading journals and has established and managed venture capital funds.
KL
KE LINamed on SEC filing
YW
Yuanzhang WangNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$1.4M disclosed across 2 rounds · 2019–2021
▶$450KraisedJan 2021 · 1 investors · PharmaceuticalsRule 506(b)
▶$450KraisedJan 2021 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- FRANK Q. LIExecutive Officer, Director
- BELLE X WANGExecutive Officer, Director
- YUANZHANG WANGDirector
- KE LIDirector
- Offering amount
- $450K
- Amount sold
- $450K
- First sale
- Jan 2021
- Incorporated
- Corporation, California
- Federal exemptions
- 06b
▶$1MraisedOct 2019 · 1 investors · PharmaceuticalsRule 506(b)
▶$1MraisedOct 2019 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- QISHENG LIExecutive Officer, Director
- KE LIDirector
- Yuanzhang WangExecutive Officer, Director
- Belle X WangExecutive Officer, Director
- Offering amount
- $1M
- Amount sold
- $1M
- First sale
- Oct 2019
- Incorporated
- Corporation, California
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Hepanova do?
- Hepanova is a clinical-stage biotech developing first-in-class oral small-molecule therapeutics for chronic liver diseases and inflammatory conditions, including MASH, liver fibrosis, and IBD. Its lead candidate, HPN-01, is an oral dual IKKα/IKKβ inhibitor that has completed a U.S. Phase 1 trial.
- Who founded Hepanova?
- Hepanova was founded by QISHENG LI, Frank Q. Li, T. Jake Liang.
- How much funding has Hepanova raised?
- Hepanova has disclosed $1.4M raised across 2 rounds.
- Where is Hepanova headquartered?
- Hepanova is headquartered in Gaithersburg, US.